MetaCap

Lantheus (LNTH) vs Oruka Therapeutics (ORKA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oruka Therapeutics (ORKA) has outperformed Lantheus (LNTH) over the past year, gaining 227.1% versus a gain of 82.9%. Over five years, LNTH leads with a +266.1% price change compared with +205.9% for ORKA. Lantheus is the larger company by market cap ($6.68 billion vs $6.50 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LNTH+82.91%ORKA+227.11%
+301%+138%-25%
Nov 21, 20251 yearNov 20, 2026
LNTH+255.87%ORKA+238.31%
+350%+129%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LNTH versus ORKA key metrics
MetricLNTHORKA
Share price$102.10$95.81
Market cap$6.68B$6.50B
1-day change0.00%-1.80%
YTD return+53.42%+216.10%
1-year return+82.91%+227.11%
5-year return+266.08%+205.91%
P/E ratio (TTM)25.40—
Forward P/E15.34—
EPS (TTM)$4.02$-2.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.54B—
Revenue growth (YoY)+0.50%—
Net income (latest FY)$233.56M$-105.43M
Gross margin61.10%—
Operating margin20.16%—
Net margin15.15%—
52-week high$111.86$115.52
52-week low$54.94$25.23
Distance from 52-week high-8.73%-17.06%
Analyst consensusholdstrong_buy
Avg. price target upside+3.81%+63.00%
Average volume1.02M965.27K
Shares outstanding65.40M67.82M
Employees1,19368
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ORKA has outperformed LNTH by 144.2 percentage points over the past year.

About Lantheus

LNTH stock →

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees

About Oruka Therapeutics

ORKA stock →

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees

LNTH vs ORKA FAQ

Which is bigger, Lantheus or Oruka Therapeutics?

Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $6.50B for Oruka Therapeutics (ORKA).

Which stock has performed better over the past year, LNTH or ORKA?

ORKA returned +227.11% over the past 12 months, compared with +82.91% for LNTH (price return, excluding dividends). Past performance does not predict future results.

Are Lantheus and Oruka Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons